# US 2013/0253196 A1 · Salts of prodrugs of piperazine and substituted piperidine antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253196 A1
- Document ID: US20130253196A1
- Status: Published application
- Kind: A1
- Application number: 13/861,804
- Filed: 2013-04-12
- Published: 2013-09-26
- Earliest claimed: 2004-03-15
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Yasutsugu Ueda; Timothy P. Connolly; John F. Kadow; Nicholas A. Meanwell; Tao Wang; Chung-Pin H. Chen; Kap-Sun Yeung; Zhongxing Zhang; David Kenneth Leahy; Shawn K. Pack; Nachimuthu Soundararajan; Pierre Sirard; Kathia Levesque; Dominique Thoraval
- Web page: https://patentgrep.com/patent/US20130253196A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/497: containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 215/10: with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C07D 471/04: Ortho-condensed systems
- C07F 9/062: {Organo-phosphoranes without P-C bonds}
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65515: {the oxygen atom being part of a five-membered ring}
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

## Claims

### Claim 1

A pharmaceutically acceptable salt of the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, having the following structure:

### Claim 2 (depends on 1)

The pharmaceutically acceptable salt of claim 1, wherein said salt is a mono tromethamine (TRIS) salt.
